Kimberly White

Healthcare communications pro, world traveler, consumer of culture - popular and otherwise - and continually amazed by current events. Opinions are my own.

[Generate:Biomedicines @generate_biomed]

Morning in Time Square.

[Generate:Biomedicines @generate_biomed]

By the numbers.
$GENB | #NasdaqListed

[Generate:Biomedicines @generate_biomed]

Introducing $GENB. We are now #NasdaqListed.

A meaningful milestone for our team — and an important step forward as we continue pioneering the AI revolution in drug design and development.

We are grateful to #TeamGenerate, our partners, and our investors who believed this work could be done.

[Nasdaq Exchange @NasdaqExchange]

Welcoming @generate_biomed [GENB] to the @NasdaqExchange Opening Bell in celebration of their listing. https://t.co/Zd3eYLC95d

[Kimberly White @kymawhite]

@JamieBonkiewicz I can do anything I want.

[Generate:Biomedicines @generate_biomed]

Missed it the first time? This Sunday, @60Minutes will re-air its segment on @nvidia's groundbreaking role in AI. The episode explores how their innovations in computing power are transforming industries—including drug discovery.

Alexandra Snyder, MD, our EVP of R&D, shares how generative AI is enabling us to unlock new possibilities in biology and create purpose-built protein therapeutics designed to address complex challenges in human health.

Tune in Sunday at 7:00pm ET on @CBS to see how technology and biology are creating bold solutions for patients.

[Generate:Biomedicines @generate_biomed]

Next week @FierceBiotech Summit 2024! Chief Corp Affairs Officer @kymawhite speaks on how communication teams shape business strategy (Mon 4pm ET), while SVP Sahm Nasseri shares insights on billion-dollar deals (Tue 11:30am ET). See full details here: https://t.co/W5bobE2moQ

[Generate:Biomedicines @generate_biomed]

How do AI & drug development expertise reshape what’s possible? In a multi-target collaboration potentially valued at over $1 billion, we are partnering with @Novartis to develop novel protein therapeutics that address critical medical needs. Learn more: https://t.co/CzMz2wyDV5

[Generate:Biomedicines @generate_biomed]

Kicking off birthday week by highlighting our founders: @NoubarAfeyan, @gibsmk, @ggrigoryanv, @AvakK, and @GVMaltzahn. Their vision and breakthroughs shaped our journey and continue to inspire us as we redefine what’s possible when biology becomes programmable

[Generate:Biomedicines @generate_biomed]

Day two of our birthday week, and we’re pulling back the curtain on our YouTube channel. Here, we’ll share our science, technology—and much, much more—as we continue to program biology and push the boundaries of what’s possible. Subscribe to our channel: https://t.co/UMKWNKr9gU

[Kimberly White @kymawhite]

@gpgomez Lots of good advice here. It gave me real pleasure to see things find a new home. Seeing furniture go to nice young families, giving them other things they admired when they came to pick something up, giving piles of books to anyone asking to take just one…..

[Generate:Biomedicines @generate_biomed]

Closing out an action-packed week for Team Generate! Our recognition on the @CNBCDisruptors 50 list was celebrated at the @NYSE – underscoring that the generative biology revolution isn’t just on its way, it’s here. Learn more about our recognition: https://t.co/l1MncaiZIg

[Kimberly White @kymawhite]

Thanks to the team at the @FT for covering the latest developments @IsomorphicLabs and our new collaborations w/@EliLillyandCo and @Novartis. https://t.co/6getlH29xE

[John D Carroll @JohnCendpts]

Andrew Dunn with a #JPM24 exclusive
Exclusive: Alphabet's Isomorphic inks first pharma deals with Eli Lilly and Novartis for $83M upfront, $2.9B in milestones
https://t.co/f2eRtr8kLX

[Fiona Marshall @FionaHMarshall]

I’m excited to share that we’re entering a strategic research collaboration with Isomorphic Labs to use state-of-the-art #AI technologies—including the next-gen model of AlphaFold—to discover novel small molecule therapeutics for select biological targets. https://t.co/yUg4PU1Mau

[Kimberly White @kymawhite]

Thanks to @AndrewE_Dunn for covering the news of @IsomorphicLabs first collaborations with @EliLillyandCo and @Novartis. This is a major testament to the promise of Iso’s platform and approach, and the potential for AI to accelerate drug discovery!

[Demis Hassabis @demishassabis]

Thrilled to announce @IsomorphicLabs collaborations with @EliLillyandCo & @Novartis potentially worth nearly $3 billion. These target-based programs represent just the start of the phenomenal real-world impact AI will have in accelerating drug discovery: https://t.co/Nz7eY1pZ14

[Kimberly White @kymawhite]

More recognition for the promise of the great work underway at Isomorphic Labs!

[Isomorphic Labs @IsomorphicLabs]

We are thrilled to be selected by the @FT as one of the ‘Tech Champions 2023’ in the Healthcare category. Read more https://t.co/ZKdJdFZn8r #AI #drugdiscovery #machinelearning

[Kimberly White @kymawhite]

Good news for drug design!

[Isomorphic Labs @IsomorphicLabs]

Today in partnership with @GoogleDeepMind we're sharing progress on the next generation of #AlphaFold Our new model greatly expands coverage of structure prediction beyond proteins to other biomolecular classes. Here's how it could advance drug design: https://t.co/ZW8DjYhVDM 🧵

[Isomorphic Labs @IsomorphicLabs]

Our CEO and recent Lasker Award winner @demishassabis shared his thoughts on how AI will change drug discovery with @AndrewE_Dunn as we were named to the 2023 #Endpoints11 list. Read more here: https://t.co/RCiBVp8wO5 #endpts #AI #drugdiscovery #machinelearning

[Kimberly White @kymawhite]

A spectacular achievement - well done!

[Demis Hassabis @demishassabis]

Deeply honoured to receive the 2023 #LaskerAward with John Jumper for our work on #AlphaFold - now used by 1M+ researchers to advance a huge range of work including drug discovery - and delighted this will bring attention to the potential of AI to enable science at digital speed!